EMA Withdrawn: Protopy (tacrolimus) — Astellas Pharma GmbH

View source ↗

Summary

Protopy (tacrolimus) has been withdrawn from the market in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Protopy (tacrolimus)

Snippet

Status: Withdrawn. Therapeutic area: Dermatitis, Atopic. MAH: Astellas Pharma GmbH. Decision date: 03/05/2007